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Association of Intestinal Alkaline Phosphatase
With Necrotizing Enterocolitis Among Premature Infants
Maya Heath, MD; Rebecca Buckley, PhD; Zeromeh Gerber, MD; Porcha Davis, MS; Laura Linneman, RN; Qingqing Gong, PhD; Brian Barkemeyer, MD; Zhide Fang, PhD;
Misty Good, MD; Duna Penn, MD; Sunyoung Kim, PhD
Abstract
IMPORTANCE Necrotizing enterocolitis (NEC) in preterm infants is an often-fatal gastrointestinal
tract emergency. A robust NEC biomarker that is not confounded by sepsis could improve bedside
management, lead to lower morbidity and mortality, and permit patient selection in randomized
clinical trials of possible therapeutic approaches.
OBJECTIVE To evaluate whether aberrant intestinal alkaline phosphatase (IAP) biochemistry in
infant stool is a molecular biomarker for NEC and not associated with sepsis.
DESIGN, SETTING, AND PARTICIPANTS This multicenter diagnostic study enrolled 136 premature
infants (gestational age, <37 weeks) in 2 hospitals in Louisiana and 1 hospital in Missouri. Data were
collected and analyzed fromMay 2015 to November 2018.
EXPOSURES Infant stool samples were collected between 24 and 40 or more weeks
postconceptual age. Enrolled infants underwent abdominal radiography at physician and hospital
site discretion.
MAINOUTCOMESANDMEASURES Enzyme activity and relative abundance of IAPweremeasured
using fluorometric detection and immunoassays, respectively. Aftermeasurementswere performed,
biochemical data were evaluated against clinical entries from infants’ hospital stay.
RESULTS Of 136 infants, 68 (50.0%) weremale infants, median (interquartile range [IQR]) birth
weight was 1050 (790-1350) g, andmedian (IQR) gestational age was 28.4 (26.0-30.9) weeks. A
total of 25 infants (18.4%) were diagnosed with severe NEC, 19 (14.0%) were suspected of having
NEC, and 92 (66.9%) did not have NEC; 26 patients (19.1%) were diagnosed with late-onset sepsis,
and 14 (10.3%) had other non–gastrointestinal tract infections. For severe NEC, suspected NEC, and
no NEC samples, median (IQR) fecal IAP content, relative to the amount of IAP in human small
intestinal lysate, was 99.0% (51.0%-187.8%) (95% CI, 54.0%-163.0%), 123.0% (31.0%-224.0%)
(95%CI, 31.0%-224.0%), and 4.8% (2.4%-9.8%) (95%CI, 3.4%-5.9%), respectively. For severe NEC,
suspected NEC, and no NEC samples, median (IQR) enzyme activity was 183 (56-507) μmol/min/g
(95% CI, 63-478 μmol/min/g) of stool protein, 355 (172-608) μmol/min/g (95% CI, 172-608
μmol/min/g) of stool protein, and 613 (210-1465) μmol/min/g (95% CI, 386-723 μmol/min/g) of stool
protein, respectively. Mean (SE) area under the receiver operating characteristic curve values for IAP
content measurements were 0.97 (0.02) (95% CI, 0.93-1.00; P < .001) at time of severe NEC, 0.97
(0.02) (95% CI, 0.93-1.00; P < .001) at time of suspected NEC, 0.52 (0.07) (95% CI, 0.38-0.66;
P = .75) at time of sepsis, and 0.58 (0.08) (95% CI, 0.42-0.75; P = .06) at time of other
non–gastrointestinal tract infections. Mean (SE) area under the receiver operating characteristic
curve values for IAP activity were 0.76 (0.06) (95% CI, 0.64-0.86; P < .001), 0.62 (0.07) (95% CI,
(continued)
Key Points
Question Unlike candidate biomarkers
inclusive for all forms of systemic
inflammation, can dysfunction in host
management of microbiota have a high
positive predictive value as a biomarker
for necrotizing enterocolitis?
Findings In this diagnostic study of 136
premature infants, high amounts of
intestinal alkaline phosphatase protein
in stool and low intestinal alkaline
phosphatase enzyme activity were
associated with diagnosis of necrotizing
enterocolitis. Therewas no association
of intestinal alkaline phosphatase
measures with non–gastrointestinal
tract infections.
Meaning Measuring the inability of
intestinal alkaline phosphatase to
maintain host-microbiota homeostasis
can potentially guide decisions for
personalized care and treatment when
an infant is most susceptible to
developing necrotizing enterocolitis.
+ Supplemental content
Author affiliations and article information are
listed at the end of this article.
Open Access. This is an open access article distributed under the terms of the CC-BY License.
JAMA Network Open. 2019;2(11):e1914996. doi:10.1001/jamanetworkopen.2019.14996 (Reprinted) November 8, 2019 1/15
Downloaded From: https://jamanetwork.com/ by a Washington University - St Louis User  on 02/28/2020
Abstract (continued)
0.48-0.77; P = .13), 0.52 (0.07) (95% CI, 0.39-0.67; P = .68), and 0.57 (0.08) (95% CI, 0.39-0.69;
P = .66), respectively.
CONCLUSIONS ANDRELEVANCE In this diagnostic study, high amounts of IAP protein in stool and
low IAP enzyme activity were associated with diagnosis of NEC andmay serve as useful biomarkers
for NEC. Our findings indicated that IAP biochemistry was uniquely able to distinguish NEC
from sepsis.
JAMA Network Open. 2019;2(11):e1914996. doi:10.1001/jamanetworkopen.2019.14996
Introduction
Necrotizing enterocolitis (NEC) is a common neonatal gastrointestinal (GI) tract emergency with a
highmortality rate1 and long-termmorbidities, including short-gut syndrome, nutritional deficiency,
and neurodevelopmental delay.2,3 Suspected NEC presents with mild, nonspecific symptoms that
frequently resolve with minimal intervention; no clinical test is an established criterion standard for
suspected NEC. Radiographic evidence, such as pneumatosis intestinalis, is used to diagnose severe
or advanced disease but has a sensitivity as low as 44%,4 has limited specificity,5 and lacks
concordance in interpretation.6-8
There have beenmany efforts to discover amolecular diagnostic biomarker for NEC (Figure 1A).
Despite the publication of more than 2500 prior biomarker studies, meta-analyses have failed to
identify an optimal NEC biomarker for routine clinical use.9-11 The design and power of these studies
raise concern: fewer than 30 articles in each decade of analysis were deemed appropriate for meta-
analysis. The focus on inflammation and repair proteins in these studies is problematic (Figure 1B).
Late-stage disease with systemic inflammatory damage is not ideal for biomarker evaluation because
no period of disease reversibility can be defined.12 Furthermore, proteins involved in inflammation
have limited positive predictive value because sepsis is a comorbidity in 35% to 60% of
NEC cases.13-17
Necrotizing enterocolitis has been argued to be the antecedent of some cases of late-onset
neonatal sepsis (LOS). Neonates, particularly very low-birth-weight infants, are susceptible to sepsis
owing to prolonged hospitalizations, invasive instrumentation, underdeveloped innate immunity,
and altered immunological responses. The latter 2 physiological states, coupled with an immature
intestinal barrier function, can give rise to NEC.18,19 From both epidemiological and clinical
standpoints, sepsis can confound the use of inflammation proteins as a biomarker for NEC. Sepsis
and NEC require careful differential diagnosis, as bothmay be lethal if not diagnosed and treated
appropriately.
Our study evaluated the use of intestinal alkaline phosphatase (IAP) as a diagnostic biomarker
for NEC. Recent findings indicate that NEC is preceded and accompanied by changes in gut
microbiota (Figure 1C) and that it is associated with host immune pathways responsible for intestinal
inflammation.19,20 Intestinal alkaline phosphatase detoxifies the surface lipopolysaccharide (LPS) of
harmful bacteria by cleaving inorganic phosphate. A component of gram-negative bacterial cell walls,
LPS is a potent inducer of innate immune signaling through toll-like receptor 4. Robust IAP function
neutralizes the LPS signal, prevents inappropriate proinflammatory signal cascades in the gut, and
contributes to beneficial microbiota maturation.
Because IAP activity precedes the initiation of signaling cascades that trigger inflammation, we
evaluated the abundance and enzyme activity of IAP shed in stool asmeasures of the pathobiological
need and ability to maintain host-microbiota homeostasis, respectively. A multicenter, prospective
diagnostic studywas conducted to assess the association of 2 IAP biochemical measures with disease
severity. As a common core protein in the human stool proteome,21 IAP is ideal for noninvasive
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testing. Content of IAP in stool is expected to increase from releasedmembrane vesicles loaded with
IAP if there were risk of bacterial-induced inflammation.22,23
Methods
StudyDesign and Participants
This study was approved by the Louisiana State University School of Medicine andWashington
University School of Medicine in St Louis institutional review board offices. This diagnostic study
followed the Standards for Reporting of Diagnostic Accuracy (STARD) 2015 reporting guideline24,25
for full reporting. During a 3-year period (May 2015 to November 2018), preterm infants born younger
than 37 weeks gestational age with a birth weight less than 1500 grams were enrolled at Children’s
Hospital of NewOrleans (n = 29; NewOrleans, Louisiana) and Touro Infirmary Hospital (n = 68; New
Orleans, Louisiana). Preterm infants born younger than 37 weeks gestational age were enrolled at St
Figure 1. Association of Necrotizing Enterocolitis (NEC) and Late-Onset SepsisWith Gut DefenseMechanisms
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Louis Children’s Hospital (n = 39; St Louis, Missouri). Written informed consent of study participants
was obtained from a parent or guardian. All infants were sought for study inclusion, thereby forming a
consecutive sampling series.
Deidentified Clinical Data
Clinical data, which included gestational age, birth weight, Apgar scores, delivery type, race/ethnicity,
sex, and disposition (ie, death, discharge, or transfer to another facility), were extracted frommedical
records every 3months. Of these, only race/ethnicity was defined by a parent. In-hospital data
included feeding, antibiotic treatment, laboratory and radiology results, and surgical notes. Clinical
findings of NEC (modified Bell stage 1-3), sepsis, and other confirmed non–GI tract infections were
reviewed by attending physicians.
Disease Definitions
Different definitions of NEC have been suggested.26-29 For this study, 2 categories of NEC, derived
from clinical documentation, were used (eTable 1 in the Supplement). Radiological signs were
defining criteria for our NEC categories; abdominal signs and clinical and laboratory findings were
secondary criteria. Suspected NECwas defined as concern for disease based on abnormal clinical and
laboratory findings without evidence of pneumatosis intestinalis or portal venous gas on abdominal
radiographic images. Severe NEC was defined by radiologic evidence of pneumatosis intestinalis
and/or portal venous gas. Patients diagnosed with spontaneous intestinal perforation (SIP) were
excluded from the study (eTable 2 in the Supplement).
Diagnosis of neonatal LOS required the appearance of abnormal clinical findings at least 72
hours after birth and blood cultures positive for bacteria not considered a contaminant30,31 (eTable 3
in the Supplement). Infants with other confirmed non–GI tract infections had clinical findings with
bacterial, viral, or fungal infections identified in body fluids other than blood. The summary of
cohorts and diagnoses of NEC, SIP, sepsis, and non–GI tract infections are provided in eTable 4 to
eTable 11 in the Supplement.
Sample Collection and Extraction of Soluble Gut Lumen Contents
A simple protocol for stool handling was developed for evaluation of IAP processes in the gut lumen
(eMethods in the Supplement). After written parental consent was obtained, samples were collected
biweekly from infant diapers and stored in a 4 °C specimen refrigerator at hospital sites until
transport to the laboratory. On receipt, stool samples were prepared for luminal content analyses,
and a 200mg/mL slurry was made with molecular grade water in a sterile microfuge tube. Following
vortexing and centrifugation, the supernatant was collected, aliquoted, and banked at −80 °C
(Figure 1E).
Protein Concentration
Total protein concentration in the stool supernatant was determined by Bradford assay
(ThermoFisher Scientific). Total protein was used to standardize biochemical activity measurements
and protein load for quantitative IAP abundance via immunoblot analyses. Protein concentration
measurement was reproducible and accurate between replicates and different operators32
(eFigure 1, eTable 12, and eMethods in the Supplement).
Fecal IAP Catalytic Activity
Alkaline phosphatase activity was measured with use of 4-methylumbelliferyl phosphate (Abcam)
substrate in the presence and absence of L-phenylalanine, an inhibitor of IAP.33,34 Relative
fluorescence units at 360/440 nmweremeasured in amultiwell format on either a Spectra MaxM2e
or i3x spectrophotometer (Molecular Devices). Total alkaline phosphatase catalysis and 10mM
phenylalanine-inhibited alkaline phosphatase catalysis were measured in triplicate and averaged.
Reported IAP activity represents the difference between these 2 averages. We reported IAP activity
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as 1 μmol of 4-methylumbelliferyl phosphate hydrolysis per minute per gram of total protein in stool
supernatant at pH 10.0; individual measurements are in eTable 13, eTable 14, and eTable 15 in the
Supplement. Intestinal alkaline phosphatase activity was reproducible between users and on
different days (eFigure 1, eTable 12, and eMethods in the Supplement).
Denaturing Gel Electrophoresis and Immunoblot
We determined IAP abundance using affinity-basedmethods and reported abundance relative to IAP
measured in control human small intestine lysate of equivalent protein load. Duplicate, precast
denaturing SDS-PAGE gels (ThermoFisher Scientific) were used to visualize proteins prior to
immunoblotting detection of IAP; 5 μg total protein was run per sample. To confirm relative protein
abundance35-37 of IAP, 2 loading controls were run on each gel. The positive control was a single lot of
human small intestinal lysate (Abcam). Purified bovine alkaline phosphatase from intestinal mucosa
(Sigma) was our negative control. Immunoblotting was performed using traditional or iBlot-iBind
methods (ThermoFisher Scientific).38-40 The amount of IAP in clinical samples was reported as a
percent of the detected protein in an immunoblot relative to the difference in densitometric pixel
count in a fixed area (Amersham Imager 600; GE Healthcare) that captured the IAP signal in the
positive and negative controls (eMethods in the Supplement). A single lot of primary antibody
against human IAP, which did not cross-react with other human alkaline phosphatase or negative
control proteins (eFigure 1C in the Supplement), and a single lot of horseradish peroxidase–
conjugated secondary antibody (Abcam) were used for all analyses. Determinations of IAP content
were linear up to 1 μg small intestinal lysate (eFigure 1D in the Supplement).
Statistical Analysis
Sample size and power calculations for planning this study were based on preliminary data acquired
from6NEC and 12 non-NEC stool samples frompremature infants. From this initial evaluation of the
effect size of IAP abundance and dysfunction, it was determined that at least 12 patients with NEC
were needed to demonstrate significant difference (ie, with a 5% CI, 2-sided, 2-sample t test, and
95% power).41 With an assumed event rate of dichotomous outcome of 10% (ie, percent preterm
infants born1.5 kgwho developNEC) and a 10%attrition rate, our target enrollmentwas 130 very low-
birth-weight infants.
Associations between inflammatory disease (NEC and non–GI tract infections), neonatal
variables, and hospital course were evaluated (Table 1 and Table 2). When characteristics or
conditions were considered antecedent or concurrent with disease modality, adjusted associations
were evaluated using logistic regressionmodels fit to the binary disease outcome. If the outcomewas
continuous (eg, the association of sepsis with the number of days in hospital), adjusted associations
were evaluated by linear regression; an analysis of variance, t test, or Kruskal-Wallis andWilcoxon test
was adopted, depending on the validation of data normality. For unadjusted comparisons or very
small counts, statistical significance was determined by χ2 or Fisher exact tests. All analyses were
completed using SAS version 9.4 (SAS Institute).
Each clinical modality was treated as a binary variable to age-appropriate controls. Differences
inmedians between NEC and control groups for IAP activity and abundancewere tested usingMann-
Whitney U test; a 2-tailed P < .05 was considered statistically significant in highlighting categorical
differences. Potential biomarker efficacy was assessed via sensitivity (true-positive rate) and
specificity (true-negative rate) calculation. For each variable of interest, specificity and sensitivity
were initially obtained using a simple threshold-based classifier. Receiver operating characteristic
curve analysis was used to evaluate sensitivity and specificity of the biomarker for the best
discrimination between infant samples with or without disease. TheWilson-Brownmethod for
confidence interval determination was used. These statistical calculations were performed using
Prism version 8.1.2 (GraphPad). All figures were generated in Igor Pro version 8.0 (Wavemetric).
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Results
A total of 136 infants were enrolled (68 [50.0%]male infants), with a median (interquartile range
[IQR]) birth weight of 1050 (790-1350) g and amedian (IQR) gestational age of 28.4 (26.0-30.9)
weeks. A total of 25 (18.4%) were classified as having severe NEC, 19 (14.0%) were suspected of
having NEC, and 92 (66.9%) had no NEC (ie, control) (Figure 1D). Of the infants with severe NEC, 19
events (76.0%) took place between 26 and 35weeks’ postconceptual age (PCA), and 6 (24.0%) took
place between 36 and 40 or more weeks’ PCA. For infants classified with suspected NEC, 16 events
(84.2%) took place between 26 and 30 weeks’ PCA, and 3 (15.8%) took place between 31 and 35
weeks’ PCA. Study participants had other forms of confirmed infections besides NEC; 26 (19.1%)
Table 1. Clinical Characteristics of PatientsWith Severe NEC, Suspected NEC, or NoNEC
Characteristic
No. (%)
P Valuea
Severe NEC
(n = 25)
Suspected NEC
(n = 19)
No NEC
(n = 92)
Birth weight, median (IQR), g 855 (700-1380) 940 (790-1190) 1100 (845-1380) .28
Gestational age at birth,
median (IQR), wk
27.6 (24.7-31.1) 28.0 (26.0-29.4) 28.7 (26.4-31.6) .48
Sex
Male 13 (52) 12 (63) 42 (46)
.39
Female 12 (48) 7 (37) 49 (54)
Race/ethnicity
African American 10 (40) 14 (74) 63 (69)
.08
Caucasian 13 (52) 5 (26) 24 (26)
Hispanic 2 (8) 0 2 (2)
Otherb 0 0 2 (2)
Cesarean delivery 20 (80) 14 (74) 62 (68) .51
Apgar scores, median (IQR)
1 min 5 (2-7) 5 (1-8) 5.5 (3-8) .75
5 min 7 (5-9) 8 (4-8) 8 (6-9) .28
First NEC episode, median (IQR)
PCA, wk 33.9 (31.0-35.7) 29.4 (28.4-30.9) NA .02
Day of life, d 21 (10-52) 13 (7-27) NA .004
Weight, g 1620 (1110-2050) 1015 (860-1377) NA <.001
Repeated NEC episodes 3 (12) 6 (32) NA .14
PCA at first stool analyzed,
median (IQR), wk
29.9 (27.9-34.3) 29.1 (27.3-30.7) 31.4 (29.0-33.7) .09
Died before discharge 3 (12) 1 (5) 5 (5.5) .44
Sepsis comorbidity
Diagnosed 9 (35) 4 (21) 13 (14)
.24
Suspected 2 (8) 2 (10) 10 (11)
Length of antibiotic treatment,
median (IQR), % of d in NICU
17 (9-25) 12 (7-20) 7 (1-8) .006
Inotrope exposure 5 (20) 3 (16) 11 (12) .53
Blood transfusions,
median (IQR), No.
Before NEC 1 (0-4) 1 (0-3) NA .77
Total 5 (2-11) 5 (1-6) 0 (0-3) <.001
NPO, median (IQR), d 10 (8-24) 7 (4-13) 2 (1-4) <.001
Exposure to human milk, %
0 4 (16) 3 (16) 8 (9)
.31
>0 to <10 4 (16) 0 10 (11)
10-50 4 (16) 2 (11) 19 (21)
51-99 3 (12) 6 (32) 27 (30)
100 10 (40) 8 (42) 27 (30)
Abbreviations: IQR, interquartile range; NA, not
applicable; NEC, necrotizing enterocolitis; NICU,
neonatal intensive care unit; NPO, nil per os; PCA,
postconceptual age.
a Using the appropriate method (analysis of variance,
Kruskal-Wallis, or Fisher exact test) to compare
differences among groups, P < .05 indicated that
there were statistically significant differences among
the 3 infant populations.
b Identified as more than 1 race by parents.
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were diagnosed with LOS, and 14 (10.3%) had a non–GI tract infection (Figure 1D). An equivalent
number of male and female infants were enrolled.
Attrition rate was 11.0% (ie, 15 infants), resulting from enrollment changes, medical changes, or
inadequate biospecimen collection (Figure 1D). A total of 6 (4.4%) patients were excluded because
of withdrawal of parental consent or death (pulmonary or multiorgan failure not related to NEC)
before sample collection. A total of 9 (6.6%) enrollees were removed because of diagnosis of SIP,
inadequate stool collection, or no stool collection during the episode of suspected or severe NEC. The
number of remaining enrollees was 121.
Demographic data and clinical histories were reviewed after stool analyses (Figure 1E). We
compiled 5400 demographic and clinical-course characteristics (Table 1 and Table 2). Potentially
confounding variables were cross-tabulated for disease. Postconceptual age and weight were the
only pre-event clinical variables associated with NEC (Table 1), supporting postnatal disease
Table 2. Clinical Characteristics of PatientsWith Other Confirmed Infections
Characteristic
No. (%)
P Valuea
Late-Onset Neonatal
Sepsis (n = 26)
Other Non–GI Tract
Infection (n = 14)
No Other
Infection(n = 96)
Birth weight, median (IQR), g 790 (670-1010) 830 (700-915) 1165 (912.5-1410) <.001
Gestational age at birth,
median (IQR), wk
25.9 (25-29.7) 26.4 (25-27.1) 29.3 (26.9-32.2) <.001
Sex
Male 11 (42.3) 6 (42.9) 50 (52.1)
.63
Female 15 (57.7) 8 (57.1) 46 (47.9)
Race/ethnicity
African American 15 (57.7) 12 (85.7) 61 (63.5)
.06
Caucasian 8 (30.8) 1 (7.1) 33 (34.4)
Hispanic 2 (7.7) 1 (7.1) 2 (2.1)
Otherb 1 (3.8) 0 1 (1.0)
Cesarean delivery 19 (73.1) 10 (71.4) 68 (70.8) >.99
Apgar scores, median (IQR)
1 min 5 (2-7) 3 (2-4) 6 (3-8) .04
5 min 7 (5-8) 6 (5-7) 8 (7-9) .002
Infection episode closest in time
to NEC, median (IQR)
PCA, wk 31.1 (28.4-34.0) 30.6 (28.7-32.3) NA .35
Day of life, d 22 (13-46) 29.5 (23-38) NA .43
Weight, g 1140 (950-1700) 1130 (955-1360) NA .78
Repeated infection episodes 19 (73.1) 9 (64.2) NA .72
PCA at first stool analyzed,
median (IQR), wk
29.8 (27.4-31.9) 29.5 (27-31.6) 31 (28.7-33.9) .06
Died before discharge 3 (11.5) 0 6 (6.3) .53
NEC comorbidity
Severe NEC 9 (34.6) 2 (14.3) 15 (15.6)
.24
Suspected NEC 4 (15.4) 2 (14.3) 13 (13.5)
Length of antibiotic treatment,
median (IQR), % of d in NICU
23 (16.7-30) 17 (11-19) 6 (0-14) <.001
Inotrope exposure 4 (15.4) 6 (42.9) 9 (9.4) .007
Blood transfusions,
median (IQR), No.
5 (2-12) 6.5 (3-11) 0 (0-2.5) <.001
NPO days, median (IQR), No. 8.5 (6-20) 6.5 (4-13) 2.5 (1-7) <.001
Exposure to human milk, %
0 1 (3.8) 2 (14.3) 12 (12.5)
.20
>0 to <10 3 (11.5) 3 (21.4) 8 (8.2)
10-50 4 (15.4) 0 21 (21.9)
51-99 9 (35.5) 6 (42.8) 22 (22.9)
100 9 (35.5) 3 (21.4) 33 (34.4)
Abbreviations: GI, gastrointestinal; IQR, interquartile
range; NA, not applicable; NEC, necrotizing
enterocolitis; NICU, neonatal intensive care unit; NPO,
nil per os; PCA, postconceptual age.
a Using the appropriate method (analysis of variance,
Kruskal-Wallis, or Fisher exact test) to compare
differences among groups, P < .05 indicated that
there were statistically significant differences among
the 3 infant populations.
b Identified as more than 1 race by parents.
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development as a consistent risk factor (median [IQR] PCA at first NEC episode: severe NEC, 33.9
[31.0-35.7] weeks; suspected NEC, 29.4 [28.4-30.9] weeks; P = .02; median [IQR] weight at first NEC
episode: severe NEC, 1620 [1110-2050] g; suspectedNEC, 1015 [860-1377] g; P < .001).18 In contrast,
birth weight and gestational age were strongly associated with risk of LOS (median [IQR] birth
weight: LOS, 790 [670-1010] g; other non–GI tract infections, 830 [700-915] g; no other non–GI tract
infection, 1165 [912.5-1410] g; P < .001; median [IQR] gestational age at birth: LOS, 25.9 [25.0-29.7]
weeks; other non–GI tract infections, 26.4 [25.0-27.1] weeks; no other non–GI tract infection, 29.3
[26.9-32.2] weeks; P < .001) (Table 2).14
Abundance of IAP Protein and IAP EnzymeActivity in PatientsWith SevereNEC,
SuspectedNEC, andNoNEC
Infants with NEC had high relative IAP content in their stool samples at the time of clinical diagnosis
(Figure 2A). Samples collected at the time of severe NEC had a median (IQR) IAP content of 99.0%
Figure 2. Association of Fecal Intestinal Alkaline Phosphatase (IAP) Content and ActivityWith Necrotizing Enterocolitis (NEC) andOther Confirmed Infections
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A, Box and violin plots of fecal abundance and activity of IAP are shown for samples
collected at the time of severe (n = 20) and suspected NEC (n = 15). Samples from
patients with no NEC (n = 86), age-matched at the time of sample collection for NEC, are
also shown. Box plot whiskers mark 9th and 91st percentiles. B, Receiver operating
characteristic curves for IAP abundance (filled circles) and activity (open circles) in
samples collected during severe (orange) or suspected (brown) NEC. C, Box and violin
plots of fecal abundance and activity of IAP are shown for samples collected during
sepsis (n = 18), other non–gastrointestinal (GI) tract infection (n = 10), and age-matched
control patients (n = 91). Box plot whiskers mark 9th and 91st percentiles. D, Receiver
operating characteristic curves of IAP abundance (filled circles) and activity (open
circles) in samples collected during sepsis (dark blue) and other non–GI tract infections
(light blue).
a P < .001
b P = .005
JAMANetworkOpen | Pediatrics Intestinal Alkaline Phosphatase and Necrotizing Enterocolitis Among Premature Infants
JAMA Network Open. 2019;2(11):e1914996. doi:10.1001/jamanetworkopen.2019.14996 (Reprinted) November 8, 2019 8/15
Downloaded From: https://jamanetwork.com/ by a Washington University - St Louis User  on 02/28/2020
(51.0%-187.8%) (95% CI, 54.0%-163.0%), whereas control samples had amedian (IQR) IAP content
of 4.8% (2.4%-9.8%) (95%CI, 3.4%-5.9%). Increased fecal IAP proteinwas associated not onlywith
severe NEC but also suspected disease. Stool samples collected at the time of NEC suspicion had a
median (IQR) IAP content of 123.0% (31.0%-224.0%) (95% CI, 31.0%-224.0%) (Figure 2A). The
median IAP abundance in stool at the time of severe NEC and suspected NECwas increased 20-fold
compared with stool collected from age-matched controls with no NEC.
Activity of IAP in samples collected during episodes of suspected and severe NECwas
significantly lower compared with samples from infants who did not have NEC (Figure 2A). However,
different levels of IAP enzyme dysfunctionwere found between patients with suspected and severe
NEC. Samples at the time of severe NEC had a median (IQR) IAP activity of 183 (56-507) μmol/min/g
(95% CI, 63-478 μmol/min/g) of stool protein. Samples at the time of suspected NEC had amedian
(IQR) IAP activity of 355 (172-608) μmol/min/g (95% CI, 172-608 μmol/min/g) of stool protein, and
IAP activity in PCA-matched control samples had a median (IQR) of 613 (210-1465) μmol/min/g (95%
CI, 386-723 μmol/min/g) of stool protein. Thus, infants with severe NEC had only a quarter of the
ability to modulate aberrant bacterial colonization as their counterparts with suspected or no NEC,
suggesting a dysfunction in host-microbial crosstalk.
Sensitivity, Specificity, and Positive Predictive Value of Fecal IAPMeasures
Accuracy, or area under the curve, of the single biochemical measure of IAP was evaluated using a
receiver operating characteristic curve, a common tool used to calculate clinical prediction rules
(Figure 2B). Mean (SE) accuracy using IAP content as a marker for severe NECwas 0.97 (0.02) (95%
CI, 0.93-1.00; P < .001), and mean (SE) accuracy using IAP activity as a marker for severe NEC was
0.76 (0.06) (95%CI, 0.64-0.86; P < .001). Similar mean (SE) accuracy values of 0.97 (0.02) (95%CI,
0.93-1.00; P < .001) for IAP content and0.62 (0.07) (95%CI, 0.48-0.77; P = .13) for IAP activity were
obtained for suspected NEC.
In contrast, IAP content and activity lacked accuracy in the diagnosis of sepsis and other non–GI
tract infections (Figure 2C). There was negligible IAP shed in stool collected at the time of clinically
defined sepsis (median [IQR], 6.5% [2.2%-23.1%]; 95% CI, 2.2%-19.8%), other non–GI tract
infections (median [IQR], 3.1% [0.8%-10.9%]; 95% CI, 0.6%-15.2%), and controls (median [IQR],
6.2% [2.7%-40.0%]; 95% CI, 4.6%-11.0%). Enzymatic ability of IAP did not differ statistically
between samples collected from these 3 cohorts (Figure 2C); median (IQR) activity for sepsis was 575
(338-1122) μmol/min/g (95% CI, 355-1073 μmol/min/g) of stool protein, for other non–GI tract
infections, 319 (207-961) μmol/min/g (95% CI, 172-1193 μmol/min/g) of stool protein, and, for the
control group, 519 (180-1243) μmol/min/g (95% CI, 350-695 μmol/min/g) of stool protein. Area
under the receiver operating characteristic curves showed that use of fecal IAP content or activity
would randomly assign culture-confirmed bacterial sepsis and other non–GI infection as positives or
negatives for these inflammatory conditions (Figure 2D).Mean (SE) accuracy scores for IAP content
were 0.52 (0.07) (95% CI, 0.38-0.66; P = .75) at the time of sepsis and 0.58 (0.08) (95% CI,
0.42-0.75; P = .06) at the time of other non–GI infection. Mean (SE) accuracy scores for IAP activity
were 0.52 (0.07) (95% CI, 0.39-0.67; P = .68) at the time of sepsis and 0.57 (0.08) (95% CI,
0.39-0.69; P = .66) at the time of other non–GI infection.
Discussion
Necrotizing enterocolitis and LOS in neonates have exaggerated inflammatory responses and a
number of common attributes. Differential diagnosis is complicated by their overlapping
presentations, diagnostic tools with limited sensitivity, and even their evolving definitions.42,43
Current criterion standards are abdominal radiography for NEC and positive blood culture for sepsis.
Yet both standards suffer from low sensitivity and the possibility of causing harm from excessive
radiation exposure or blood sampling. Lastly, outcome reports are problematic: interpretations of
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subtle radiological findings are subjective andmay vary, whereas culture results may take up to 48 to
72 hours.
There have been numerous attempts to identify candidate markers of gut injury that
discriminate NEC from other inflammatory conditions.44-48 Animal NECmodels suggest that the
immune dysregulation andmicrobial dysbiosis associated with severe NEC are tandem host-bacterial
missteps owing to excessive toll-like receptor 4 signaling in response to bacterial LPS.19,49-52 The
majority of candidate NEC biomarkers are proteins further downstream from the initial host signaling
steps. Elevations in platelet activating factor,3,53 inter-α inhibitor protein,54 calprotectin, claudin,48
intestinal fatty acid binding protein,55 and C-reactive protein56 in plasma have been associated with
NEC onset. Taken together, current literature points toward the idea that diagnosis of advancedNEC
is a clinical descriptor of terminal-stage pathologic processes,29,57 suggesting that anNEC biomarker
may always be confounded by sepsis.
Our study challenged these theories. Biomarkers, such as calprotectin, are reliable indicators of
intestinal inflammation in general but provide no understanding of the dominant inflammatory
pathways at work in the intestinal mucosa of a patient. Our study required prospective inclusion of
infants with NEC and concurrently tested healthy and unhealthy controls with several inflammatory
conditions in the neonatal intensive care unit. Under these real-life conditions, estimates of
biomarker reliability more accurately reflected potential performance in clinical application.
Examination of proteins involved in organ-specific modulation of microbiota homeostasis and
response distinguished NEC from other forms of inflammation. As such, IAP is the first candidate
diagnostic biomarker, unique in its high positive predictive value for NEC. Importantly, IAP is
associated with NEC and not associated with sepsis or other non–GI tract infections.
Using a protein that is an established antecedent to inflammation, induced by LPS, as a
biomarker has support from prior studies. There are several models of IAP activation in gut dysbiosis:
exosomes, increased gut permeability, and/or intestinal epithelial injury. It has not been clarified
whether the bacterial translocation across the gut epithelium that can give rise to LOS is a native
outcome from altered gut epithelial permeability or a result of gut barrier deterioration. Our IAP
study does not address whether there is deterioration of the gut endothelium in NEC or sepsis.
However, detection of IAP in such high abundance in our stool samples during NEC episodes
suggested that there is active regulation of lipid vesicle secretion into the gut lumen during active
NEC disease; such secretion of IAP is not detectable in stool during LOS. This investigation does not
support the idea that NEC shares the same pathobiological mechanism as neonatal sepsis.
The IAP biomarker is associated with disease severity; IAP biochemistry differentiates advanced
NEC, flagged by portal venous gas or pneumatosis intestinalis, from suspected disease, for which
there are no reliably observable signs by radiology. Our results also showed that this classification of
NEC suspicion is supported as an explicit disease state. Our approach differed fromother candidate
biomarker studies. This work diverges not only by the target protein of interest but also by our use of
a disease severity catalog, biospecimen choice, andmolecular method of detection. Wewere able
to segregate NEC suspicion from severe cases of NEC. There has been great effort to identify
commonalities in clinical criteria to define severe NEC. Very few reports on NEC suspicion are
published because of the absence of a molecular diagnostic test and lack of definition consensus.
This study showed that suspected and severe NECwere associated with the active release of IAP in
infant stool. It also demonstrated that there were clear differences in IAP function in these 2 disease
categories. AdvancedNECwas associatedwith severe biochemical dysfunction of host IAP, whereas
suspected NEC has only partial loss of IAP enzyme activity. In contrast, C-reactive protein and other
biomarkers are not associated with Bell staging,11 and importantly, the values do not significantly
vary between suspected and severe NEC.
Our findings did differ from the other studies evaluating IAP as a biomarker for NEC. Our
research report used not 1 but 2 measures to evaluate IAP biochemistry in patient samples, as
follows: (1) immunoblotting to quantify its relative abundance in comparison with the amount of IAP
found in human small intestine and (2) enzymatic activity to identify whether the protein is
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functional and capable of modulating microbial dysbiosis. Both approaches are necessary to
distinguish disease pathways and differences between individuals. Serological tests58 of alkaline
phosphatase as an NEC biomarker reported that the amount of IAP in blood was increased in infants
with NEC compared with controls, suggesting that IAPmay play a role in NEC pathogenesis. Serum
is not an ideal sampling source, as 4 different alkaline phosphatases are present, and their relative
levels in serum are known to change during gestation59 (eFigure 1 and eFigure 2 in the Supplement).
Although prior conclusions drawn58 support our findings, sole use of denaturing protein gels cannot
provide equivalent evidence that IAP was identified nor is it capable of quantifying the amount of
alkaline phosphatase in general.
Limitations
Limitations to this study include sporadic stooling patterns associated with prematurity, which did
not permit standardized collection times. Furthermore, not all NEC samples were obtained, as there
is often decreased stooling with acute illness. However, given the noninvasive nature of stool
collection, this process offers clear clinical advantages over serological testing that can lead to
iatrogenic blood loss in infants.
Conclusions
In conclusion, the results of this study indicated that themeasurement of IAP dysfunction in stool is
a biomarker for NEC with better sensitivity and specificity than other candidates previously reported
in the literature. Although promising, use of fecal IAP as a biomarker should be considered an adjunct
in establishing the diagnosis of severe NEC, monitoring disease progression, and surveilling high-
risk infant groups. Normative data across different PCAs are needed for appropriate design and
analysis of future biomarker studies to determine whether fecal IAP can serve as a diagnostic proxy
at themolecular level. The clinical potential of this noninvasive tool lies in its ability to identify infants
most at risk of developing NEC, to facilitate management of feeding and antibiotic regimens, and to
monitor response to treatment.
ARTICLE INFORMATION
Accepted for Publication: September 19, 2019.
Published:November 8, 2019. doi:10.1001/jamanetworkopen.2019.14996
OpenAccess: This is an open access article distributed under the terms of the CC-BY License. © 2019 HeathM et al.
JAMA Network Open.
Corresponding Author: Sunyoung Kim, PhD, Department of Biochemistry andMolecular Biology, Louisiana State
University School of Medicine and Health Sciences Center, 1901 Perdido St, NewOrleans, LA 70112 (skim3@
lsuhsc.edu).
Author Affiliations:Department of Pediatrics and Neonatology, Louisiana State University School of Medicine,
Children’s Hospital of NewOrleans, NewOrleans (Heath, Gerber, Barkemeyer, Penn); Department of Biochemistry
andMolecular Biology, Louisiana State University School of Medicine and Health Sciences Center, NewOrleans
(Buckley, Davis, Kim); Division of NewbornMedicine, Department of Pediatrics, Washington University School of
Medicine in St Louis, St Louis Children’s Hospital, St Louis, Missouri (Linneman, Gong, Good); Department of
Biostatistics, Louisiana State University School of Public Health, NewOrleans (Fang).
Author Contributions:Dr Kim had full access to all of the data in the study and takes responsibility for the integrity
of the data and the accuracy of the data analysis. Drs Heath and Buckley had equal authorship contribution.
Concept and design:Heath, Buckley, Gerber, Barkemeyer, Penn, Kim.
Acquisition, analysis, or interpretation of data:Heath, Buckley, Gerber, Davis, Linneman, Gong, Fang, Good,
Penn, Kim.
Drafting of the manuscript:Heath, Buckley, Gerber, Davis, Kim.
JAMANetworkOpen | Pediatrics Intestinal Alkaline Phosphatase and Necrotizing Enterocolitis Among Premature Infants
JAMA Network Open. 2019;2(11):e1914996. doi:10.1001/jamanetworkopen.2019.14996 (Reprinted) November 8, 2019 11/15
Downloaded From: https://jamanetwork.com/ by a Washington University - St Louis User  on 02/28/2020
Critical revision of the manuscript for important intellectual content:Heath, Buckley, Linneman, Gong, Barkemeyer,
Fang, Good, Penn, Kim.
Statistical analysis: Buckley, Fang, Penn, Kim.
Obtained funding: Barkemeyer, Good, Kim.
Administrative, technical, or material support:Heath, Buckley, Gerber, Davis, Linneman, Gong, Barkemeyer, Good,
Penn, Kim.
Supervision: Barkemeyer, Good, Penn, Kim.
Conflict of Interest Disclosures:Drs Buckley, Gerber, Penn, and Kim reported having patent 16/267 120 pending,
which is a direct outcome of the work in this article. Dr Good reported having a sponsored research agreement
with AstarteMedical Partners, consulting for Abbott Laboratories, and having a patent for the use of interleukin 22
in treating necrotizing enterocolitis pending outside the submitted work. Dr Kim reported having a financial
relationship with NewOrleans Bioinnovation Center and Jefferson Parish Economic Development Commission
outside the submitted work and being the founder of a spin-out company, Chosen Diagnostics Inc, which is
considering an option to license the diagnostic test developed from this work. No other disclosures were reported.
Funding/Support: This work was supported by grant R01GM097350 to Dr Kim from the National Institutes of
Health, grant R41HD095779 to Drs Buckley and Kim from the National Institutes of Health, grants K08DK101608,
R03DK111473, and R01DK118568 to Dr Good from the National Institutes of Health, grants IIP-1713220 and
IIP-1547932 to Drs Buckley and Kim from the National Science Foundation, grant 5-FY17-79 to Dr Good from the
March of Dimes, grant LEQSF-RD-D-07 to Dr Kim from the Louisiana Board of Regents, and grant HSCNO-2017-
LIFT-006 to Dr Kim from the Louisiana State University Leveraging Innovation for Technology Transfer Fund. Dr
Good is supported by the Children’s Discovery Institute of Washington University and St Louis Children’s Hospital
and the Department of Pediatrics at Washington University School of Medicine, St Louis. Drs Barkemeyer, Kim,
and Heath are supported by the Louisiana State University School of Medicine. Drs Heath, Gerber, and Kim are
supported by the Louisiana State University Health Foundation.
Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection,
management, analysis, and interpretation of the data; preparation, review, or approval of themanuscript; and
decision to submit themanuscript for publication.
Additional Contributions: This work is dedicated to the patients and families who participated in this study.
Nurses and neonatologists at the clinical sites were central to the success of this study and are recognized for their
dedication to excellent patient care. Eleanor Holmgren, BS (Louisiana State University Health Sciences Center),
provided technical assay contributions, and Jessie Guidry, MS (Director of Proteomics Core, Louisiana State
University School of Medicine), providedmass spectral analyses. LucynaWojcik (Louisiana State University Health
Sciences Center) made eFigure 2 in the Supplement. They were not compensated for their time.
Additional Information:Data will be shared and are provided in the online supplement. Individual patient data, a
data dictionary that defines each field in the data set, and supporting documentation are provided. There are no
restrictions on the use of the data.
REFERENCES
1. Lin PW, Stoll BJ. Necrotising enterocolitis. Lancet. 2006;368(9543):1271-1283. doi:10.1016/S0140-6736(06)
69525-1
2. YeeWH, Soraisham AS, Shah VS, Aziz K, YoonW, Lee SK; Canadian Neonatal Network. Incidence and timing of
presentation of necrotizing enterocolitis in preterm infants. Pediatrics. 2012;129(2):e298-e304. doi:10.1542/peds.
2011-2022
3. Young C, Sharma R, Handfield M, Mai V, Neu J. Biomarkers for infants at risk for necrotizing enterocolitis: clues
to prevention? Pediatr Res. 2009;65(5 Pt 2):91R-97R. doi:10.1203/PDR.0b013e31819dba7d
4. Tam AL, Camberos A, Applebaum H. Surgical decision making in necrotizing enterocolitis and focal intestinal
perforation: predictive value of radiologic findings. J Pediatr Surg. 2002;37(12):1688-1691. doi:10.1053/jpsu.
2002.36696
5. Hoehn T, Stöver B, Bührer C. Colonic pneumatosis intestinalis in preterm infants: different to necrotising
enterocolitis with a more benign course? Eur J Pediatr. 2001;160(6):369-371. doi:10.1007/s004310100757
6. Mata AG, Rosengart RM. Interobserver variability in the radiographic diagnosis of necrotizing enterocolitis.
Pediatrics. 1980;66(1):68-71.
7. Rehan VK, Seshia MM, Johnston B, ReedM,Wilmot D, Cook V. Observer variability in interpretation of
abdominal radiographs of infants with suspected necrotizing enterocolitis. Clin Pediatr (Phila). 1999;38(11):
637-643. doi:10.1177/000992289903801102
JAMANetworkOpen | Pediatrics Intestinal Alkaline Phosphatase and Necrotizing Enterocolitis Among Premature Infants
JAMA Network Open. 2019;2(11):e1914996. doi:10.1001/jamanetworkopen.2019.14996 (Reprinted) November 8, 2019 12/15
Downloaded From: https://jamanetwork.com/ by a Washington University - St Louis User  on 02/28/2020
8. Di Napoli A, Di Lallo D, Perucci CA, et al. Inter-observer reliability of radiological signs of necrotising enterocolitis
in a population of high-risk newborns. Paediatr Perinat Epidemiol. 2004;18(1):80-87. doi:10.1111/j.1365-3016.
2003.00517.x
9. Evennett NJ, Petrov MS, Mittal A, Windsor JA. Systematic review and pooled estimates for the diagnostic
accuracy of serological markers for intestinal ischemia.World J Surg. 2009;33(7):1374-1383. doi:10.1007/s00268-
009-0074-7
10. Terrin G, Stronati L, Cucchiara S, De Curtis M. Serummarkers of necrotizing enterocolitis: a systematic review.
J Pediatr Gastroenterol Nutr. 2017;65(6):e120-e132. doi:10.1097/MPG.0000000000001588
11. Rusconi B, GoodM,Warner BB. Themicrobiome and biomarkers for necrotizing enterocolitis: are we any closer
to prediction? J Pediatr. 2017;189:40-47.e2.
12. Garg BD, Sharma D, Bansal A. Biomarkers of necrotizing enterocolitis: a review of literature. J Matern Fetal
Neonatal Med. 2018;31(22):3051-3064. doi:10.1080/14767058.2017.1361925
13. Uauy RD, Fanaroff AA, Korones SB, Phillips EA, Phillips JB, Wright LL; National Institute of Child Health and
Human Development Neonatal Research Network. Necrotizing enterocolitis in very low birth weight infants:
biodemographic and clinical correlates. J Pediatr. 1991;119(4):630-638. doi:10.1016/S0022-3476(05)82418-7
14. Stoll BJ, Hansen N, Fanaroff AA, et al. Late-onset sepsis in very low birth weight neonates: the experience of
the NICHDNeonatal Research Network. Pediatrics. 2002;110(2 Pt 1):285-291. doi:10.1542/peds.110.2.285
15. Kaufman D, Fairchild KD. Clinical microbiology of bacterial and fungal sepsis in very-low-birth-weight infants.
Clin Microbiol Rev. 2004;17(3):638-680. doi:10.1128/CMR.17.3.638-680.2004
16. Sharma R, Tepas JJ III, HudakML, et al. Neonatal gut injury and infection rate: impact of surgical debridement
on outcome. Pediatr Surg Int. 2005;21(12):977-982. doi:10.1007/s00383-005-1539-x
17. Cole CR, Hansen NI, Higgins RD, et al; Eunice Kennedy Shriver National Institute of Child Health and Human
Development’s Neonatal Research Network. Bloodstream infections in very low birth weight infants with intestinal
failure. J Pediatr. 2012;160(1):54-9.e2.
18. Neu J, Walker WA. Necrotizing enterocolitis. N Engl J Med. 2011;364(3):255-264. doi:10.1056/
NEJMra1005408
19. Nanthakumar N, Meng D, Goldstein AM, et al. Themechanism of excessive intestinal inflammation in
necrotizing enterocolitis: an immature innate immune response. PLoS One. 2011;6(3):e17776. doi:10.1371/journal.
pone.0017776
20. Mai V, Young CM, UkhanovaM, et al. Fecal microbiota in premature infants prior to necrotizing enterocolitis.
PLoS One. 2011;6(6):e20647. doi:10.1371/journal.pone.0020647
21. Lichtman JS, Marcobal A, Sonnenburg JL, Elias JE. Host-centric proteomics of stool: a novel strategy focused
on intestinal responses to the gut microbiota.Mol Cell Proteomics. 2013;12(11):3310-3318. doi:10.1074/mcp.
M113.029967
22. Shifrin DA Jr, McConnell RE, Nambiar R, Higginbotham JN, Coffey RJ, TyskaMJ. Enterocytemicrovillus-derived
vesicles detoxify bacterial products and regulate epithelial-microbial interactions. Curr Biol. 2012;22(7):627-631.
doi:10.1016/j.cub.2012.02.022
23. Shifrin DA Jr, Tyska MJ. Ready…aim…fire into the lumen: a new role for enterocyte microvilli in gut host
defense. Gut Microbes. 2012;3(5):460-462. doi:10.4161/gmic.21247
24. Cohen JF, Korevaar DA, Altman DG, et al. STARD 2015 guidelines for reporting diagnostic accuracy studies:
explanation and elaboration. BMJ Open. 2016;6(11):e012799. doi:10.1136/bmjopen-2016-012799
25. Bossuyt PM, Cohen JF, Gatsonis CA, Korevaar DA; STARD group. STARD 2015: updated reporting guidelines for
all diagnostic accuracy studies. Ann Transl Med. 2016;4(4):85.
26. Bell MJ. Neonatal necrotizing enterocolitis. N Engl J Med. 1978;298(5):281-282. doi:10.1056/
NEJM197802022980519
27. Gephart SM, Spitzer AR, Effken JA, Dodd E, Halpern M, McGrath JM. Discrimination of GutCheck(NEC):
a clinical risk index for necrotizing enterocolitis. J Perinatol. 2014;34(6):468-475. doi:10.1038/jp.2014.37
28. Battersby C, Longford N, Costeloe K, Modi N; UK Neonatal Collaborative Necrotising Enterocolitis Study
Group. Development of a gestational age-specific case definition for neonatal necrotizing enterocolitis. JAMA
Pediatr. 2017;171(3):256-263. doi:10.1001/jamapediatrics.2016.3633
29. Gephart SM, Gordon PV, Penn AH, et al. Changing the paradigm of defining, detecting, and diagnosing NEC:
perspectives on Bell’s stages and biomarkers for NEC. Semin Pediatr Surg. 2018;27(1):3-10. doi:10.1053/j.
sempedsurg.2017.11.002
JAMANetworkOpen | Pediatrics Intestinal Alkaline Phosphatase and Necrotizing Enterocolitis Among Premature Infants
JAMA Network Open. 2019;2(11):e1914996. doi:10.1001/jamanetworkopen.2019.14996 (Reprinted) November 8, 2019 13/15
Downloaded From: https://jamanetwork.com/ by a Washington University - St Louis User  on 02/28/2020
30. Buhimschi CS, Bhandari V, Hamar BD, et al. Proteomic profiling of the amniotic fluid to detect inflammation,
infection, and neonatal sepsis. PLoS Med. 2007;4(1):e18. doi:10.1371/journal.pmed.0040018
31. Buhimschi CS, Buhimschi IA, Abdel-Razeq S, et al. Proteomic biomarkers of intra-amniotic inflammation:
relationship with funisitis and early-onset sepsis in the premature neonate. Pediatr Res. 2007;61(3):318-324. doi:
10.1203/01.pdr.0000252439.48564.37
32. Marcus E. Credibility and reproducibility. Cell. 2014;159(5):965-966. doi:10.1016/j.cell.2014.11.016
33. FishmanWH, Green S, Inglis NI. L-phenylalanine: an organ specific, stereospecific inhibitor of human intestinal
alkaline phosphatase. Nature. 1963;198:685-686. doi:10.1038/198685b0
34. Fernley HN,Walker PG. Inhibition of alkaline phosphatase by L-phenylalanine. Biochem J. 1970;116(3):
543-544. doi:10.1042/bj1160543
35. Jensen KJ, Garmaroudi FS, Zhang J, et al. An ERK-p38 subnetwork coordinates host cell apoptosis and necrosis
during coxsackievirus B3 infection. Cell Host Microbe. 2013;13(1):67-76. doi:10.1016/j.chom.2012.11.009
36. Kang BH, Jensen KJ, Hatch JA, Janes KA. Simultaneous profiling of 194 distinct receptor transcripts in human
cells. Sci Signal. 2013;6(287):rs13. doi:10.1126/scisignal.2003624
37. Bose AK, Janes KA. A high-throughput assay for phosphoprotein-specific phosphatase activity in cellular
extracts.Mol Cell Proteomics. 2013;12(3):797-806. doi:10.1074/mcp.O112.024059
38. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to
nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A. 1979;76(9):4350-4354. doi:10.
1073/pnas.76.9.4350
39. Burnette WN. “Western blotting”: electrophoretic transfer of proteins from sodium dodecyl sulfate–
polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated
protein A. Anal Biochem. 1981;112(2):195-203. doi:10.1016/0003-2697(81)90281-5
40. Spinola SM, Cannon JG. Different blocking agents cause variation in the immunologic detection of proteins
transferred to nitrocellulose membranes. J Immunol Methods. 1985;81(1):161-165. doi:10.1016/0022-1759(85)
90132-2
41. DangQ,Mazumdar S, Houck PR. Sample size and power calculations based on generalized linearmixedmodels
with correlated binary outcomes. Comput Methods Programs Biomed. 2008;91(2):122-127. doi:10.1016/j.cmpb.
2008.03.001
42. Wynn JL. Defining neonatal sepsis. Curr Opin Pediatr. 2016;28(2):135-140. doi:10.1097/MOP.
0000000000000315
43. Marik PE, Taeb AM. SIRS, qSOFA and new sepsis definition. J Thorac Dis. 2017;9(4):943-945. doi:10.21037/jtd.
2017.03.125
44. Hintz SR, Kendrick DE, Stoll BJ, et al; NICHD Neonatal Research Network. Neurodevelopmental and growth
outcomes of extremely low birth weight infants after necrotizing enterocolitis. Pediatrics. 2005;115(3):696-703.
doi:10.1542/peds.2004-0569
45. Derikx JP, Evennett NJ, Degraeuwe PL, et al. Urine based detection of intestinal mucosal cell damage in
neonates with suspected necrotising enterocolitis. Gut. 2007;56(10):1473-1475. doi:10.1136/gut.2007.128934
46. Guthmann F, Börchers T, Wolfrum C,Wustrack T, Bartholomäus S, Spener F. Plasma concentration of
intestinal- and liver-FABP in neonates suffering from necrotizing enterocolitis and in healthy preterm neonates.
Mol Cell Biochem. 2002;239(1-2):227-234. doi:10.1023/A:1020508420058
47. Sylvester KG, Ling XB, Liu GY, et al. A novel urine peptide biomarker-based algorithm for the prognosis of
necrotising enterocolitis in human infants. Gut. 2014;63(8):1284-1292. doi:10.1136/gutjnl-2013-305130
48. Thuijls G, Derikx JP, vanWijck K, et al. Non-invasive markers for early diagnosis and determination of the
severity of necrotizing enterocolitis. Ann Surg. 2010;251(6):1174-1180. doi:10.1097/SLA.0b013e3181d778c4
49. Afrazi A, Sodhi CP, RichardsonW, et al. New insights into the pathogenesis and treatment of necrotizing
enterocolitis: Toll-like receptors and beyond. Pediatr Res. 2011;69(3):183-188. doi:10.1203/PDR.
0b013e3182093280
50. Morowitz MJ, Poroyko V, CaplanM, Alverdy J, Liu DC. Redefining the role of intestinal microbes in the
pathogenesis of necrotizing enterocolitis. Pediatrics. 2010;125(4):777-785. doi:10.1542/peds.2009-3149
51. Sodhi CP, Neal MD, Siggers R, et al. Intestinal epithelial Toll-like receptor 4 regulates goblet cell development
and is required for necrotizing enterocolitis in mice. Gastroenterology. 2012;143(3):708-718.e5, e705.
52. Nanthakumar NN, Fusunyan RD, Sanderson I, Walker WA. Inflammation in the developing human intestine:
a possible pathophysiologic contribution to necrotizing enterocolitis. Proc Natl Acad Sci U S A. 2000;97(11):
6043-6048. doi:10.1073/pnas.97.11.6043
JAMANetworkOpen | Pediatrics Intestinal Alkaline Phosphatase and Necrotizing Enterocolitis Among Premature Infants
JAMA Network Open. 2019;2(11):e1914996. doi:10.1001/jamanetworkopen.2019.14996 (Reprinted) November 8, 2019 14/15
Downloaded From: https://jamanetwork.com/ by a Washington University - St Louis User  on 02/28/2020
53. Rabinowitz SS, Dzakpasu P, Piecuch S, Leblanc P, Valencia G, Kornecki E. Platelet-activating factor in infants at
risk for necrotizing enterocolitis. J Pediatr. 2001;138(1):81-86. doi:10.1067/mpd.2001.110132
54. Chaaban H, Shin M, Sirya E, Lim YP, CaplanM, Padbury JF. Inter-alpha inhibitor protein level in neonates
predicts necrotizing enterocolitis. J Pediatr. 2010;157(5):757-761. doi:10.1016/j.jpeds.2010.04.075
55. Evennett NJ, Hall NJ, Pierro A, Eaton S. Urinary intestinal fatty acid-binding protein concentration predicts
extent of disease in necrotizing enterocolitis. J Pediatr Surg. 2010;45(4):735-740. doi:10.1016/j.jpedsurg.2009.
09.024
56. Pourcyrous M, Korones SB, YangW, Boulden TF, Bada HS. C-reactive protein in the diagnosis, management,
and prognosis of neonatal necrotizing enterocolitis. Pediatrics. 2005;116(5):1064-1069. doi:10.1542/peds.
2004-1806
57. Gordon P, Christensen R, Weitkamp JH, Maheshwari A. Mapping the newworld of necrotizing enterocolitis
(NEC): review and opinion. EJ Neonatol Res. 2012;2(4):145-172.
58. Kampanatkosol R, Thomson T, Habeeb O, et al. The relationship between reticulated platelets, intestinal
alkaline phosphatase, and necrotizing enterocolitis. J Pediatr Surg. 2014;49(2):273-276. doi:10.1016/j.jpedsurg.
2013.11.037
59. McLachlan R, Coakley J, Murton L, Campbell N. Plasma intestinal alkaline phosphatase isoenzymes in
neonates with bowel necrosis. J Clin Pathol. 1993;46(7):654-659. doi:10.1136/jcp.46.7.654
SUPPLEMENT.
eMethods. Clinical Data, Disease Definitions, and Biospecimen Collection and Analysis
eTable 1. Study Criteria Used to Classify Diagnosis and Suspicion of Neonatal Necrotizing Enterocolitis
eTable 2. Study Criteria Used for Focal or Spontaneous Intestinal Perforation
eTable 3. Study Criteria Used to Define Pathogenic Infection Outside the Gastrointestinal Tract
eTable 4. Summary of NEC Cohorts at Different Clinical Sites
eTable 5. List of 25 Radiologically Confirmed (Severe) Cases of Necrotizing Enterocolitis Enrolled
eTable 6. List of 19 Suspected Necrotizing Enterocolitis Cases Enrolled
eTable 7. List of 3 Enrolled InfantsWith Spontaneous Intestinal Perforation (SIP) and Necrotizing Enterocolitis
eTable 8. List of 86 Enrolled InfantsWhoWere Neither Clinically DiagnosedWith nor Suspected of Having
Necrotizing Enterocolitis
eTable 9. Summary of Sepsis and Other Non–GI Tract Infection Cohorts at Different Clinical Sites
eTable 10. List of All 26 Late-Onset Neonatal Sepsis Cases Enrolled
eTable 11. List of All 14 Cases of Confirmed, Non–GI Tract Infections in Urine, Bone, or Trachea
eTable 12. Accuracy and Reproducibility of In Vitro Measurements of Gut Lumen Content
eTable 13. IAPMeasurements From 20 Stool Samples at the Time of Severe Necrotizing Enterocolitis
eTable 14. IAPMeasurements From 15 Stool Samples at the Time of Necrotizing Enterocolitis Suspicion
eTable 15. IAPMeasurements From 86 Enrolled InfantsWhoWere Neither Clinically DiagnosedWith nor
Suspected of Having Necrotizing Enterocolitis
eTable 16. Proteins Identified in Preterm Gut Lumen (N = 635)
eFigure 1. Control Experiments Demonstrated Operator Reproducibility, Antibody Reagent Specificity, and
Biospecimen Specificity
eFigure 2. Sequence Alignment of 4 Human Alkaline Phosphatases and Calf Intestinal Alkaline Phosphatase
eReferences
JAMANetworkOpen | Pediatrics Intestinal Alkaline Phosphatase and Necrotizing Enterocolitis Among Premature Infants
JAMA Network Open. 2019;2(11):e1914996. doi:10.1001/jamanetworkopen.2019.14996 (Reprinted) November 8, 2019 15/15
Downloaded From: https://jamanetwork.com/ by a Washington University - St Louis User  on 02/28/2020
